Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 26Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 19Neoplasm Metastasis 17Colorectal Neoplasms 17Ovarian Neoplasms 15Lymphoma, Non-Hodgkin 15Carcinoma, Renal Cell 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Myelodysplastic Syndromes 11Lung Neoplasms 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Prostatic Neoplasms 9Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Adenocarcinoma 9Thyroid Neoplasms 8

Interventions

pembrolizumab 1brigatinib 1Paclitaxel 1Crizotinib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has announcements × Carcinoma, Squamous Cell × Clear all
NCT04472429 2025-11-03

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Incyte Corporation

Phase 3 Completed
308 enrolled 17 charts 1 FDA
Gastrointestinal

Anus Neoplasms, Carcinoma, Squamous Cell

NCT03284424 2024-08-23

MK-3475-629

Merck Sharp & Dohme LLC

Phase 2 Completed
159 enrolled 16 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT02737501 2021-08-20

ALTA-1L

Takeda

Phase 3 Completed
275 enrolled 23 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡